AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1564212 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase with intravenous heparin
Number of subjects: 41600
Study 1564212 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated recombinant tissue-type plasminogen activator (rt-PA) with intravenous heparin
Number of subjects: 41600
Study 1564212 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of streptokinase, rt-PA and intravenous heparin
Number of subjects: 41600
Study 6377076 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 70
Study 6377076 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection treatment
Number of subjects: 70
Study 31204383 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple small incisions and negative-pressure wound therapy (NPWT)
Number of subjects: 0
Study 31204383 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional comprehensive treatment with additional small incisions and NPWT
Number of subjects: 0
Study 31204383 — intervention group
Group type: COMPARATOR
Intervention: Traditional comprehensive treatment
Number of subjects: 0
Study 30522663 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose drug-coated balloon (DCB)
Number of subjects: 294
Study 30522663 — intervention group
Group type: COMPARATOR
Intervention: Uncoated percutaneous transluminal angioplasty balloon (PTA)
Number of subjects: 294
Study 25961604 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-controlled task difficulty during early practice
Number of subjects: 0
Study 25961604 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial self-control of task difficulty
Number of subjects: 0
Study 25961604 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control during early practice
Number of subjects: 0
Study 24658598 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral double-dose esomeprazole 40 mg twice daily (n=93)
Number of subjects: 293
Study 24658598 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral standard-dose esomeprazole 40 mg once daily (n=94)
Number of subjects: 293
Study 24658598 — intervention group
Group type: COMPARATOR
Intervention: Control group (Rockall scores <6, n=89)
Number of subjects: 293
Study 22508707 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 50
Study 22508707 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 50
Study 19766977 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment with usual obstetric care
Number of subjects: 144
Study 19766977 — intervention group
Group type: COMPARATOR
Intervention: Usual obstetric care and sham ultrasound treatment
Number of subjects: 144
Study 19766977 — intervention group
Group type: COMPARATOR
Intervention: Usual obstetric care only
Number of subjects: 144
Study 19061696 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring using wireless telemetry
Number of subjects: 2000
Study 19061696 — intervention group
Group type: COMPARATOR
Intervention: Standard in-office care
Number of subjects: 2000
Study 16260511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralow-dose transdermal estradiol (0.014 mg/d)
Number of subjects: 417
Study 16260511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 11876692 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐11 15 microg/kg once weekly
Number of subjects: 148
Study 11876692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 11876692 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐11 7.5 microg/kg twice weekly
Number of subjects: 148
Study 10206248 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nail and wire towrope (Group A)
Number of subjects: 30
Study 10206248 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary nail and external fixation device (Group B)
Number of subjects: 30
Study 9592325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin
Number of subjects: 110
Study 9592325 — intervention group
Group type: COMPARATOR
Intervention: Lomefloxacin
Number of subjects: 110
Study 9592325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin (open trial)
Number of subjects: 110
Study 1670631 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g oral sulfasalazine plus 20 mg twice daily rectal prednisolone enemas (group I, N = 18)
Number of subjects: 37
Study 1670631 — intervention group
Group type: COMPARATOR
Intervention: 2.0 g twice daily rectal sucralfate enemas plus oral placebo (group II, N = 19)
Number of subjects: 37
Study 6623019 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroid anti-inflammatory drugs (NSAIDs)
Number of subjects: 68
Study 6623019 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission-inducing drugs (RIDs)
Number of subjects: 68
Study 6623019 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical score
Number of subjects: 68
Study 6623019 — intervention group
Group type: COMPARATOR
Intervention: Laboratory tests (erythrocyte sedimentation rate and serum C-reactive protein)
Number of subjects: 68
Study 30411599 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual intercourse on the night before the tests
Number of subjects: 10
Study 30411599 — intervention group
Group type: COMPARATOR
Intervention: No sexual intercourse on the five days prior to the tests (control condition)
Number of subjects: 10
Study 28235887 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin administration to evoke coughs
Number of subjects: 0
Study 28235887 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine administration to induce bronchoconstriction
Number of subjects: 0
Study 28235887 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 26965791 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 35 mg qd
Number of subjects: 113
Study 26965791 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg qd
Number of subjects: 113
Study 26965791 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg tid
Number of subjects: 113
Study 25251396 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery goals
Number of subjects: 0
Study 25251396 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-approach goals
Number of subjects: 0
Study 25251396 — intervention group
Group type: COMPARATOR
Intervention: Negative feedback (for any task type)
Number of subjects: 0
Study 25251396 — intervention group
Group type: COMPARATOR
Intervention: Negative feedback for the rule-finding task
Number of subjects: 0
Study 21707770 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for self-management
Number of subjects: 64
Study 21707770 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 64
Study 20071147 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (n=23)
Number of subjects: 200
Study 20071147 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (n=93)
Number of subjects: 200
Study 20071147 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (n=57)
Number of subjects: 200
Study 20071147 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment response
Number of subjects: 200
Study 20071147 — intervention group
Group type: EXPERIMENTAL
Intervention: Catatonia signs
Number of subjects: 200
Study 20071147 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergent validity of DSM-IV catatonia signs
Number of subjects: 200
Study 20071147 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance of DSM-IV criteria
Number of subjects: 200
Study 17646216 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated sit‐to‐stands using a GrandStand System
Number of subjects: 66
Study 17646216 — intervention group
Group type: COMPARATOR
Intervention: Knee extensions using ankle cuff weights (Control)
Number of subjects: 66
Study 15701470 — intervention group
Group type: COMPARATOR
Intervention: Atrioventricular conventional pacing (Group A)
Number of subjects: 0
Study 15701470 — intervention group
Group type: EXPERIMENTAL
Intervention: Atriobiventricular pacing (Group B)
Number of subjects: 0
Study 15701470 — intervention group
Group type: COMPARATOR
Intervention: Crossover to atrioventricular conventional pacing (after initial 3 months of atrio-biventricular pacing)
Number of subjects: 0
Study 15701470 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover back to atrio-biventricular pacing (after initial 3 months of atrioventricular conventional pacing)
Number of subjects: 0
Study 15701470 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal pacing therapy
Number of subjects: 0
Study 12075254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular rate control
Number of subjects: 4060
Study 12075254 — intervention group
Group type: COMPARATOR
Intervention: Rhythm control
Number of subjects: 4060
Study 10207960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel (Coloplast), n = 17
Number of subjects: 32
Study 10207960 — intervention group
Group type: COMPARATOR
Intervention: Wet saline compresses, n = 15
Number of subjects: 32
Study 7499006 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg b.i.d.
Number of subjects: 12
Study 7499006 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg q.d.
Number of subjects: 12
Study 7499006 — intervention group
Group type: COMPARATOR
Intervention: 14-hydroxy metabolite with 500 mg q.d.
Number of subjects: 12
Study 7499006 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-hydroxy metabolite with 250 mg b.i.d.
Number of subjects: 12
Study 1933049 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine alone
Number of subjects: 15
Study 1933049 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine plus smoking
Number of subjects: 15
Study 1933049 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 15
Study 1933049 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus smoking
Number of subjects: 15
Study 1933049 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 15
Study 1933049 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 15
Study 6786895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 0.8 g daily
Number of subjects: 45
Study 6786895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31993753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy (OC) - cooling the mouth with ice for ≥ 30 minutes during chemotherapy infusions.
Number of subjects: 53
Study 31993753 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral cryotherapy).
Number of subjects: 53
Study 31993753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy (OC).
Number of subjects: 53
Study 30685420 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice supplementation (12.4 mmol NO3− per day for 7 days)
Number of subjects: 12
Study 30685420 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice supplementation
Number of subjects: 12
Study 27208923 — intervention group
Group type: EXPERIMENTAL
Intervention: SFO + LEU (4.2 g of leucine)
Number of subjects: 18
Study 27208923 — intervention group
Group type: COMPARATOR
Intervention: SFO + ALA (4.2 g of alanine)
Number of subjects: 18
Study 25280603 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyrobak (Radiancy, Hod-hasharon, Israel) self-treatment for 10 minutes, one to three times per day, for 3 weeks
Number of subjects: 36
Study 25280603 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyrobak (Radiancy, Hod-hasharon, Israel) self-treatment
Number of subjects: 36
Study 25280603 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (WLC) group
Number of subjects: 36
Study 23528101 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIII-FS prophylaxis (25 IU kg(‐1), three times weekly)
Number of subjects: 84
Study 23528101 — intervention group
Group type: COMPARATOR
Intervention: On-demand treatment
Number of subjects: 84
Study 21900595 — intervention group
Group type: COMPARATOR
Intervention: Alcohol intake levels of 3.4 g/d or less
Number of subjects: 41836
Study 21900595 — intervention group
Group type: COMPARATOR
Intervention: Alcohol intake levels of more than 3.4 g/d
Number of subjects: 41836
Study 21900595 — intervention group
Group type: COMPARATOR
Intervention: Alcohol intake levels of 30 g/d or less
Number of subjects: 41836
Study 21900595 — intervention group
Group type: COMPARATOR
Intervention: Alcohol intake levels of more than 30 g/d
Number of subjects: 41836
Study 21900595 — intervention group
Group type: COMPARATOR
Intervention: Alcohol intake levels by quartile distributions
Number of subjects: 41836
Study 21900595 — intervention group
Group type: COMPARATOR
Intervention: Alcohol intake levels and MSI-, CIMP-, or BRAF-defined CRC subtypes
Number of subjects: 41836
Study 19143021 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional radiofrequency (FRF) treatment using Renesis device, delivering RF energy at 72 degrees C for 4 seconds.
Number of subjects: 0
Study 17589656 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary stimulation (group 1)
Number of subjects: 31
Study 17589656 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouth rinses (group 2)
Number of subjects: 31
Study 15231555 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised cognitive-behavioural therapy (CBT)
Number of subjects: 274
Study 15231555 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 274
Study 12359854 — intervention group
Group type: EXPERIMENTAL
Intervention: BSE instruction group
Number of subjects: 266064
Study 12359854 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 266064
Study 9842383 — intervention group
Group type: EXPERIMENTAL
Intervention: Soil lead abatement (replacement of contaminated soil with clean soil)
Number of subjects: 187
Study 9842383 — intervention group
Group type: COMPARATOR
Intervention: Control group (no soil lead abatement)
Number of subjects: 187
Study 8205873 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable monitoring using MESAM 4
Number of subjects: 349
Study 2683452 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective studies in orthopedics
Number of subjects: 0
Study 2683452 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical studies in orthopedics
Number of subjects: 0
Study 2683452 — intervention group
Group type: EXPERIMENTAL
Intervention: Test statistics in orthopedic studies
Number of subjects: 0
Study 370042 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of supplementary vitamin C daily
Number of subjects: 42
Study 370042 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 42
Study 30382496 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential practice schedule
Number of subjects: 40
Study 30382496 — intervention group
Group type: EXPERIMENTAL
Intervention: Success orientation
Number of subjects: 40
Study 30382496 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-only goal
Number of subjects: 40
Study 28077734 — intervention group
Group type: COMPARATOR
Intervention: 1 egg/d
Number of subjects: 38
Study 28077734 — intervention group
Group type: COMPARATOR
Intervention: 2-3 eggs/d
Number of subjects: 38
Study 28077734 — intervention group
Group type: COMPARATOR
Intervention: 3 eggs/d
Number of subjects: 38
Study 28077734 — intervention group
Group type: COMPARATOR
Intervention: 0 eggs/d
Number of subjects: 38
Study 26094093 — intervention group
Group type: EXPERIMENTAL
Intervention: Karydakis flap (K-flap)
Number of subjects: 321
Study 26094093 — intervention group
Group type: COMPARATOR
Intervention: Excision with healing by secondary intention (EHSI)
Number of subjects: 321
Study 23494898 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Disclosure Protocol (GDP) - writing about the patient's diagnosis and treatment for 15 minutes a day over 3 days
Number of subjects: 102
Study 23494898 — intervention group
Group type: COMPARATOR
Intervention: Control - writing about what the patient did the previous day for 15 minutes a day over 3 days
Number of subjects: 102
Study 22180357 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/d, n = 47)
Number of subjects: 134
Study 22180357 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/d, n = 45)
Number of subjects: 134
Study 22180357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 42)
Number of subjects: 134
Study 19691482 — intervention group
Group type: COMPARATOR
Intervention: Tirofiban (50 ng mL(‐1))
Number of subjects: 12
Study 19691482 — intervention group
Group type: EXPERIMENTAL
Intervention: PSI-697 (low-dose 2 m)
Number of subjects: 12
Study 19691482 — intervention group
Group type: EXPERIMENTAL
Intervention: PSI-697 (high-dose 20 m)
Number of subjects: 12
Study 17378888 — intervention group
Group type: EXPERIMENTAL
Intervention: Vector fluid polish (VU-H)
Number of subjects: 20
Study 17378888 — intervention group
Group type: COMPARATOR
Intervention: Supragingival polishing (PO-H)
Number of subjects: 20
Study 17378888 — intervention group
Group type: COMPARATOR
Intervention: Hand instruments (HI-H) performed by a hygienist
Number of subjects: 20
Study 17378888 — intervention group
Group type: COMPARATOR
Intervention: Hand instruments (HI-D) performed by a dentist
Number of subjects: 20
Study 15142020 — intervention group
Group type: EXPERIMENTAL
Intervention: Sand surface (S condition)
Number of subjects: 16
Study 15142020 — intervention group
Group type: COMPARATOR
Intervention: Wood surface (F condition)
Number of subjects: 16
Study 11468942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine pediatric solution (0.15 mg/kg once daily)
Number of subjects: 60
Study 11468942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine pediatric solution
Number of subjects: 60
Study 11468942 — intervention group
Group type: COMPARATOR
Intervention: Reference population design with 10 samples per child
Number of subjects: 60
Study 9694025 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 200 microg
Number of subjects: 12
Study 9694025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7832669 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC-MOPD method
Number of subjects: 29
Study 7832669 — intervention group
Group type: COMPARATOR
Intervention: Standard insemination methods
Number of subjects: 29
Study 2856549 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 2856549 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 2856549 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 0
Study 31847733 — intervention group
Group type: EXPERIMENTAL
Intervention: Convex optimization‐based interactive segmentation approach
Number of subjects: 46
Study 30247714 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation (21 g protein, 3 g total leucine, 9 g carbohydrate, 3 g fat; n = 21)
Number of subjects: 41
Study 30247714 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 g protein, 25 g carbohydrate, 6 g fat; n = 20)
Number of subjects: 41
Study 30247714 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Number of subjects: 41
Study 30247714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 28643799 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept treatment initiated for nAMD
Number of subjects: 5620
Study 26632710 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy based on E‐test results (rabeprazole + bismuth potassium citrate + amoxicillin + clarithromycin) for 14 days
Number of subjects: 90
Study 26632710 — intervention group
Group type: COMPARATOR
Intervention: Empirical therapy (rabeprazole + bismuth potassium citrate + amoxicillin + clarithromycin)
Number of subjects: 90
Study 25098068 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose antibiotic before inguinal hernia mesh repair
Number of subjects: 166
Study 25098068 — intervention group
Group type: COMPARATOR
Intervention: Placebo before inguinal hernia mesh repair
Number of subjects: 166
Study 22030224 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm olein (PO) diet
Number of subjects: 45
Study 22030224 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil (CO) diet
Number of subjects: 45
Study 22030224 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin olive oil (OO) diet
Number of subjects: 45
Study 18351203 — intervention group
Group type: EXPERIMENTAL
Intervention: Supracrestal gingival tissue measurements
Number of subjects: 100
Study 17030771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 813
Study 14687438 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10-40 mg
Number of subjects: 0
Study 14687438 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 10-80 mg
Number of subjects: 0
Study 14687438 — intervention group
Group type: COMPARATOR
Intervention: simvastatin 10-80 mg
Number of subjects: 0
Study 14687438 — intervention group
Group type: COMPARATOR
Intervention: pravastatin 10-40 mg
Number of subjects: 0
Study 10750679 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal employment
Number of subjects: 171
Study 10750679 — intervention group
Group type: EXPERIMENTAL
Intervention: History of prenatal employment
Number of subjects: 171
Study 10750679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to work after delivery
Number of subjects: 171
Study 10750679 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest
Number of subjects: 171
Study 9042739 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal auditory stimuli
Number of subjects: 0
Study 9042739 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal stimuli in conjunction with visual information
Number of subjects: 0
Study 9042739 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal-visual combination
Number of subjects: 0
Study 1525588 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine treatment
Number of subjects: 0
Study 1525588 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal thyroidectomy
Number of subjects: 0
Study 1525588 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic glucocorticoids
Number of subjects: 0
Study 1525588 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study 4025299 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A behavior pattern (A1-A2) in usual care
Number of subjects: 3110
Study 4025299 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A behavior pattern (A1-A2) in special intervention
Number of subjects: 3110